deltatrials
Completed PHASE1 NCT00895362

Erlotinib in Combination With Cetuximab

A Phase I Dose-Escalation Study of Erlotinib in Combination With Cetuximab in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.

Sponsor: M.D. Anderson Cancer Center

Conditions Advanced Cancers
Interventions Cetuximab Erlotinib
Updated 5 times since 2017 Last updated: Jul 10, 2015 Started: Apr 30, 2009 Primary completion: Jul 31, 2015

This PHASE1 trial investigates Advanced Cancers and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States